Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, two unique mutations in the RBPJ gene were identified and linked to Adams-Oliver syndrome, confirming impaired DNA binding of mutated RBPJ as a factor in this rare genetic disorder.

This study observed that innervation of the mystacial pad in rats by fine-caliber axons is more extensive and complex than previously described, with distinct differences in labeling patterns depending on the tracer and survival time.

This case report details a 42-year-old woman with Rhupus, a rare overlap syndrome of rheumatoid arthritis and systemic lupus erythematosus, emphasizing diagnostic challenges due to non-specific clinical criteria and documenting symptoms like inflammatory arthritis, malar rash, and hematological abnormalities.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

In this study, researchers found that RORA directly regulates the expression of the Bnip3 gene, which is crucial for hair follicle stem cell health, using rat HFSCs as a model. They propose that targeting RORA could modulate HFSC status.

This study concluded that the receptor-like kinase ERULUS, regulated by auxin, is crucial for modulating cell wall composition and pectin dynamics during root hair growth in Arabidopsis.

RCS-01 is safe and may help rejuvenate aging skin.

This study found that patients with rosacea had significantly more radiological evidence of chronic rhinosinusitis, and erythematotelangiectatic severity was associated with CRS.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

This study identified hair follicle stem cells as a source of squamous cell carcinoma in an inducible mouse model and proposes targeting these for future cancer therapies.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This case report describes a 42-year-old woman with Rhupus, a rare overlap syndrome of rheumatoid arthritis and systemic lupus erythematosus, highlighting challenges in diagnosis due to non-specific clinical criteria and documenting specific symptoms such as inflammatory arthritis, malar rash, and hematological abnormalities observed during follow-up.

This study found that a specific mutation in the mouse RXRalpha gene significantly impacts immune responses and causes hair loss and skin cysts.

This article discusses the potential benefits of decade-wise Rasayana therapy in enhancing female reproductive health by addressing various life stages, from pre-menarche to post-menopause, and draws from traditional and contemporary sources to conceptualize its importance.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

In this study, rabies virus antigens were detected in the outer root sheath of the follicle-sinus complex in the muzzle skin of rabid dogs, suggesting its usefulness as an alternative diagnostic specimen.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this case report, a 20-year-old male with tricho-rhino-phalangeal syndrome was found to have a de novo frameshift mutation in the TRPS1 gene, highlighting the challenges in diagnosing this rare disorder.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This article discusses the clinical spectrum and pathobiology of radiotherapy-induced alopecia and reports no new research findings, highlighting potential pathways for future targeted RIA management.

Retinoic acid causes gland formation instead of hair in mouse skin by altering epidermal and dermal interactions.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.